73
Participants
Start Date
December 14, 2007
Primary Completion Date
January 27, 2016
Study Completion Date
February 6, 2020
CliniMACS
Miltenyi Biotec CliniMACS stem cell selection device
Stem cell transplantation
An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
Fludarabine
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Thioplex®
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
L-phenylalanine mustard
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Mycophenolate mofetil
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Rituxan™
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Alemtuzumab
After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
Cyclophosphamide
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Anti-thymocyte globulin (Rabbit)
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
G-CSF
Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Muromonab
Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
St. Jude Children's Research Hospital, Memphis
St. Jude Children's Research Hospital
OTHER